The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement
Open accessAbstract
Purpose: ROS1 rearrangement is a distinct molecular subset of non–small-cell lung cancer (NSCLC). We investigated the efficacy and safety of ceritinib in patients with ROS1-rearranged NSCLC. Patients and Methods: We enrolled 32 patients with advanced NSCLC who tested positive for ROS1 rearrangement by fluorescent in situ hybridization. Ceritinib 750 mg was administered once daily. The primary end point was objective response rate. The secondary end points were disease control rate; duration of response; progression-free survival; overall survival; toxicity; and concordance among fluorescent in situ hybridization, immunohistochemistry, and next-generation sequencing. Results: Between June 7, 2013, and February 1, 2016, 404 patients underwent ROS1 prescreening, and 32 patients with ROS1 rearrangement were enrolled. All patients except two were crizotinib-naïve. At the time of data cutoff, the median follow-up was 14.0 months, and 18 patients (56%) had discontinued treatment. Of the 32 patients enrolled, 28 were evaluable for response by independent radiologic review. Objective response rate was 62% (95% CI, 45% to 77%), with one complete response and 19 partial responses; duration of response was 21.0 months (95% CI, 17 to 25 months); and disease control rate was 81% (95% CI, 65% to 91%). The median progression-free survival was 9.3 months (95% CI, 0 to 22 months) for all patients and 19.3 months (95% CI, 1 to 37 months) for crizotinib-naïve patients. The median overall survival was 24 months (95% CI, 5 to 43 months). Of the eight patients with brain metastases, intracranial disease control was reported in five (63%; 95% CI, 31% to 86%). The most common adverse events (majority, grade 1 or 2) for all treated patients were diarrhea (78%), nausea (59%), and anorexia (56%). Conclusion: Ceritinib demonstrated potent clinical activity in patients with ROS1-rearranged NSCLC who were heavily treated previously with multiple lines of chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
Self-citationFrampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555
Anchored multiplex PCR for targeted next-generation sequencing
Zheng, Z., Liebers, M., Zhelyazkova, B., Cao, Y., Panditi, D., Lynch, K. D., Chen, J., Robinson, H. E., Shim, H. S., Chmielecki, J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3729 · Cited by 915
Self-citationKim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00614-2 · Cited by 471
Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
Davies, K. D., Le, A. T., Theodoro, M. F., Skokan, M. C., Aisner, D. L., Berge, E. M., Terracciano, L. M., Cappuzzo, F., Incarbone, M., Roncalli, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0550 · Cited by 464
Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1
Awad, M. M., Katayama, R., McTigue, M., Liu, W., Deng, Y.-L., Brooun, A., Friboulet, L., Huang, D., Falk, M. D., Timofeevski, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215530 · Cited by 416
McDermott, U., Iafrate, A. J., Gray, N. S., Shioda, T., Classon, M., Maheswaran, S., Zhou, W., Choi, H. G., Smith, S. L., Dowell, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6186 · Cited by 399
Mazières, J., Zalcman, G., Crinò, L., Biondani, P., Barlesi, F., Filleron, T., Dingemans, A.-M. C., Léna, H., Monnet, I., Rothschild, S. I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3302 · Cited by 369
Cited by
The biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,392
Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer: A Review
Arbour, K. C., & Riely, G. J. (2019) · JAMA · doi:10.1001/jama.2019.11058 · Cited by 1,060
Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.009 · Cited by 853
Mateo, J., Chakravarty, D., Dienstmann, R., Jezdic, S., Gonzalez-Perez, A., Lopez-Bigas, N., Ng, C. K. Y., Bedard, P. L., Tortora, G., Douillard, J.-Y., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy263 · Cited by 815
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Tan, A. C., & Tan, D. S. W. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01626 · Cited by 779
Non‐small cell lung cancer in China
Chen, P., Liu, Y., Wen, Y., & Zhou, C. (2022) · Cancer Communications · doi:10.1002/cac2.12359 · Cited by 656
Update 2020: Management of Non-Small Cell Lung Cancer
Alexander, M., Kim, S. Y., & Cheng, H. (2020) · Lung · doi:10.1007/s00408-020-00407-5 · Cited by 648
Shaw, A. T., Riely, G. J., Bang, Y.-J., Kim, D.-W., Camidge, D. R., Solomon, B. J., Varella-Garcia, M., Iafrate, A. J., Shapiro, G. I., Usari, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz131 · Cited by 576
Drilon, A., Siena, S., Dziadziuszko, R., Barlesi, F., Krebs, M. G., Shaw, A. T., de Braud, F., Rolfo, C., Ahn, M.-J., Wolf, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30690-4 · Cited by 528
Self-citationDrilon, A., Ou, S.-H. I., Cho, B. C., Kim, D.-W., Lee, J., Lin, J. J., Zhu, V. W., Ahn, M.-J., Camidge, D. R., Nguyen, J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0484 · Cited by 504
Self-citationHanna, N. H., Schneider, B. J., Temin, S., Baker, S., Brahmer, J., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03022 · Cited by 456
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Huang, L., Jiang, S., & Shi, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00977-0 · Cited by 456
Advances in systemic therapy for non-small cell lung cancer
Miller, M., & Hanna, N. (2021) · BMJ · doi:10.1136/bmj.n2363 · Cited by 366
Shaw, A. T., Solomon, B. J., Chiari, R., Riely, G. J., Besse, B., Soo, R. A., Kao, S., Lin, C.-C., Bauer, T. M., Clancy, J. S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30655-2 · Cited by 358
Emerging therapeutic agents for advanced non-small cell lung cancer
Chen, R., Manochakian, R., James, L., Azzouqa, A.-G., Shi, H., Zhang, Y., Zhao, Y., Zhou, K., & Lou, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00881-7 · Cited by 340
Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
Chevallier, M., Borgeaud, M., Addeo, A., & Friedlaender, A. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i4.217 · Cited by 316
A comprehensive review of protein kinase inhibitors for cancer therapy
Kannaiyan, R., & Mahadevan, D. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1527688 · Cited by 302
Hanna, N. H., Robinson, A. G., Temin, S., Baker, S., Brahmer, J. R., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03570 · Cited by 300
ROS1-dependent cancers — biology, diagnostics and therapeutics
Drilon, A., Jenkins, C., Iyer, S., Schoenfeld, A., Keddy, C., & Davare, M. A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0408-9 · Cited by 294
Wu, Y.-L., Planchard, D., Lu, S., Sun, H., Yamamoto, N., Kim, D.-W., Tan, D. S. W., Yang, J. C.-H., Azrif, M., Mitsudomi, T., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 291
Recent Advances in Targeting ROS1 in Lung Cancer
Lin, J. J., & Shaw, A. T. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.08.002 · Cited by 261
Patil, T., Smith, D. E., Bunn, P. A., Aisner, D. L., Le, A. T., Hancock, M., Purcell, W. T., Bowles, D. W., Camidge, D. R., & Doebele, R. C. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.001 · Cited by 205
Kim, S.-Y., Kim, S.-M., Lim, S., Lee, J. Y., Choi, S.-J., Yang, S.-D., Yun, M. R., Kim, C. G., Gu, S. R., Park, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-5026 · Cited by 151
Self-citationLong-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
Drilon, A., Chiu, C.-H., Fan, Y., Cho, B. C., Lu, S., Ahn, M.-J., Krebs, M. G., Liu, S. V., John, T., Otterson, G. A., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100332 · Cited by 113
Self-citationPapadopoulos, K. P., Borazanci, E., Shaw, A. T., Katayama, R., Shimizu, Y., Zhu, V. W., Sun, T. Y., Wakelee, H. A., Madison, R., Schrock, A. B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1630 · Cited by 113
Ou, S.-H. I., Fujiwara, Y., Shaw, A. T., Yamamoto, N., Nakagawa, K., Fan, F., Hao, Y., Gao, Y., Jänne, P. A., & Seto, T. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100108 · Cited by 40
Advances and future directions in ROS1 fusion-positive lung cancer
Boulanger, M. C., Schneider, J. L., & Lin, J. J. (2024) · The Oncologist · doi:10.1093/oncolo/oyae205 · Cited by 38
Metadata
- Authors
- Lim, S. M., Kim, H. R., Lee, J.-S., Lee, K. H., Lee, Y.-G., Min, Y. J., Cho, E. K., Lee, S. S., Kim, B.-S., Choi, M. Y., Shim, H. S., Chung, J.-H., La Choi, Y., Lee, M. J., Kim, M., Kim, J.-H., Ali, S. M., Ahn, M.-J., & Cho, B. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-08-10
- Volume
- 35
- Issue
- 23
- Pages
- 2613-2618
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2614720739
- Cited by
- 301
- References
- 22
- FWCI
- 31.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.